Viral hepatitis: Indian scenario

Publication date: July 2016 Source:Medical Journal Armed Forces India, Volume 72, Issue 3 Author(s): Sandeep Satsangi, Yogesh K. Chawla Viral hepatitis is a cause for major health care burden in India and is now equated as a threat comparable to the “big three” communicable diseases – HIV/AIDS, malaria and tuberculosis. Hepatitis A virus and Hepatitis E virus are predominantly enterically transmitted pathogens and are responsible to cause both sporadic infections and epidemics of acute viral hepatitis. Hepatitis B virus and Hepatitis C virus are predominantly spread via parenteral route and are notorious to cause chronic hepatitis which can lead to grave complications including cirrhosis of liver and hepatocellular carcinoma. Around 400million people all over the world suffer from chronic hepatitis and the Asia-Pacific region constitutes the epicentre of this epidemic. The present article would aim to cover the basic virologic aspects of these viruses and highlight the present scenario of viral hepatitis in India.
Source: Medical Journal Armed Forces India - Category: Journals (General) Source Type: research

Related Links:

This study not only represents the most systematic analysis of codon usage patterns in PEDV orf3 genes, but also provides a basic shaping mechanism of the codon usage bias.
Source: Research in Veterinary Science - Category: Veterinary Research Source Type: research
CONCLUSION: The results of the Keynote-048 study have already led to the approval of pembrolizumab in the first line for platin-sensitive HNSCC in the USA and the expected approval in Europe will presumably change the therapeutic landscape in the long term. In the future, effective therapies for patients without a response to programmed cell death 1 (PD-1)/PD-L1 inhibition will be needed. PMID: 31612261 [PubMed - as supplied by publisher]
Source: HNO - Category: ENT & OMF Tags: HNO Source Type: research
Publication date: Available online 16 October 2019Source: Chemico-Biological InteractionsAuthor(s): Yasmeen M. Attia, Dina M. El-Kersh, Reham A. Ammar, Aliaa Adel, Aya Khalil, Hoda Walid, Kirullos Eskander, Mohamed Hamdy, Nada Reda, Nour Elhoda Mohsen, Ghada M. Al-Toukhy, Mohamed Tarek Mansour, Mohamed M. ElmazarAbstractTreatment of breast cancer by paclitaxel (PAX) often encounters therapeutic failure most likely caused by innate/acquired resistance. Cancer stem cells (CSCs) and multidrug resistance complex (MDR-1 or P-glycoprotein) overexpression are main mechanisms implicated in chemoresistance. Increased aldehyde dehro...
Source: Chemico Biological Interactions - Category: Biochemistry Source Type: research
Conclusions: Our study shows that ingenol mebutate is highly efficacious field treatment for actinic keratosis. PMID: 31616223 [PubMed]
Source: Advances in Dermatology and Allergology - Category: Dermatology Tags: Postepy Dermatol Alergol Source Type: research
Conclusions: The PIPAC is safe and is not a burdensome or aggressive form of therapy, especially according to the very important factors influencing the potential quality of hair and hair loss. The authors, however, realize that to obtain comprehensive results and evaluate this novel and promising method we need to perform more research without any limitations like those in our study. PMID: 31616222 [PubMed]
Source: Advances in Dermatology and Allergology - Category: Dermatology Tags: Postepy Dermatol Alergol Source Type: research
Authors: KamiƄska-Winciorek G, Cybulska-Stopa B, Lugowska I, Ziobro M, Rutkowski P Abstract The introduction of immunotherapy into the treatment of cancer patients has revolutionised the oncological approach and significantly improved patient survival. The key drugs are immune checkpoint inhibitors (CPIs), whose mechanism of action is to elicit immune response against cancer cell antigens. Three types of CPIs are currently used and approved: an anti-CTLA-4 antibody, ipilimumab; anti-PD-1 antibodies, nivolumab and pembrolizumab; and anti-PD-L1 antibodies: atezolizumab, avelumab and durvalumab. CPIs have been widely...
Source: Advances in Dermatology and Allergology - Category: Dermatology Tags: Postepy Dermatol Alergol Source Type: research
In this study, we aimed to explore the efficacy and safety profile of apatinib monotherapy, or combined with chemotherapy or endothelial growth factor receptor (EGFR)-TKI in heavily pretreated non-small cell lung cancer (NSCLC) patients with brain metastases. We performed a retrospective analysis for relapsed NSCLC patients with brain metastases from our institute, whom received apatinib (250mg or 500mg p.o. qd) monotherapy, or combination with EGFR-TKI or chemotherapy as second- or more line systemic therapy until disease progression or unacceptable toxicity occurred. The objective response rate (ORR), disease control rat...
Source: Oncology Research - Category: Cancer & Oncology Tags: Oncol Res Source Type: research
The opioid epidemic has taken its toll on Missouri. According to the Centers for Disease Control and Prevention, drug-related deaths rose in Missouri last year even as national deaths fell. One part of the problem? Legally prescribed pills. According to data from the U.S. Drug Enforcement Administration made available by The Washington Post, 1.6 billion prescription pain pills (oxycodone and hydrocodone) were supplied to Missouri pharmacies between 2006 and 2012, the most recent yea r that data…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
Conclusion: rs28362491 polymorphism was significantly associated with the risk of HNCs, especially with NC. Additionally, our results showed that no association was discovered between rs2233406 polymorphism and HNCs. PMID: 31612070 [PubMed - in process]
Source: Disease Markers - Category: Laboratory Medicine Tags: Dis Markers Source Type: research
Publication date: Available online 16 October 2019Source: Academic RadiologyAuthor(s): He An, Keith W.H. Chiu, K.Y. Tse, Hextan Y.S. Ngan, Pek-Lan Khong, Elaine Y.P. LeeRationale and ObjectivesTo evaluate the diagnostic performance of contrast-enhanced computed tomography (CT) in predicting residual disease following neo-adjuvant chemotherapy (NACT) in stage III/IV ovarian cancer.Materials and MethodsThis was a retrospective observational cohort study including consecutive patients with primary stage III/IV ovarian cancer who received NACT before interval debulking surgery. CT findings before interval debulking surgerywere...
Source: Academic Radiology - Category: Radiology Source Type: research
More News: Cancer & Oncology | Carcinoma | Cirrhosis | Epidemics | Epidemiology | General Medicine | Health | Health Management | Hepatitis | Hepatitis A | Hepatitis B | Hepatitis C | Hepatocellular Carcinoma | HIV AIDS | Liver | Liver Cancer | Malaria | Tuberculosis | Urology & Nephrology | Virology